Tony Ng

Senior Vice President and Head of Oncology Translational Research · GSK · company speakers →

Professor Tony Ng (FMEDSCI, MB ChB, MRCP, FRCPath, PhD) brings a rich spectrum of knowledge and capabilities with clinical experience in treating AIDS patients (with opportunistic infections and cancers) and fundamental immunology skills. He is also a pioneer of molecular imaging in cancer. He was the first person to use antibody based fluorescence lifetime imaging (FLIM) approaches in tumour cells and tissues to monitor protein states and function. He has adopted a multidisciplinary approach to understand cancer recurrence and also to stratify molecularly targeted agents in combination with immunotherapy. His research bridges the gap between physics, biology and medicine, particularly in the field of translational cancer research.<br /> <br /> For clinical translation, he has the proven ability to coordinate and work cooperatively with colleagues and leaders in a wide variety of disciplines (imaging, cell biology, oncology, bioinformatics, surgery, pathology, genomics, as well as physical science disciplines such as mathematics, physics, chemistry and engineering). He has directed the KCL and UCL Comprehensive Cancer Imaging Centre (CCIC, one of four centres funded by CRUK &amp; EPSRC in the UK) between 2008 and 2019. For his multidisciplinary research contribution in cancer research he was elected to the UK Academy of Medical Sciences as a Fellow (FMedSci) in 2013 and was elected as a Fellow of the European Academy of Cancer Sciences in 2017.<br /> <br /> Within KCL, Tony Ng has been the Director of the Comprehensive Cancer Centre at King&rsquo;s College London between 2017 and 2023. In 2022, he joined GSK as a Vice President in Oncology R&amp;D on a part-time basis, to help establish the GSK-KCL Translational Oncology Research Hub which was announced in September 2021. The aim is to apply his clinical medicine training as well as immunology, biochemistry and imaging expertise to accelerate the development of the anti-cancer drugs. His experience of collaborating

Is this you? Claim this profile →